Former Viela CEO Bing Yao finds his next gig — bringing Chinese R&D innovation stateside

Nicole DeFeudis

Editor

When Horizon Therapeutics bought out Viela Bio for $53 a share, everyone wondered what then-CEO Bing Yao would do next — including himself. Three months …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Former Viela CEO Bing Yao finds his next gig — bringing Chinese R&D innovation stateside

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump 2.0 blog: Wayback Machine is insufficient for US health data, judge says

Travere plans to seek expanded label for kidney drug despite failed trial

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Biohaven lands priority review on second-chance application for neurodegenerative drug

What will pharma's share buyback shopping spree mean for M&A?

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

For­mer Viela CEO Bing Yao finds his next gig — bring­ing Chi­nese R&D in­no­va­tion state­side

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Former Viela CEO Bing Yao finds his next gig — bringing Chinese R&D innovation stateside